Hyloris Partners with Colonis Pharma for UK Launch of Innovative Dental Product

Hyloris Pharmaceuticals SA ( (DE:52U) ) has shared an announcement.

Hyloris Pharmaceuticals has announced an exclusive licence and distribution agreement with Colonis Pharma for XTRAZA, a novel oral rinse designed to aid patients on anticoagulant therapies during dental procedures. This partnership aims to enhance patient care in the UK by addressing a specific clinical need, while Hyloris will receive milestone payments tied to regulatory achievements and exclusively supply XTRAZA in the region. This move is expected to strengthen Hyloris’s market position and contribute to the healthcare industry by providing a targeted solution for dental procedures involving blood thinners.

More about Hyloris Pharmaceuticals SA

Hyloris Pharmaceuticals SA is a specialty biopharma company dedicated to reinventing existing medications to address unmet medical needs. The company’s development strategy leverages established regulatory pathways to reduce clinical burdens and shorten development timelines. Based in Liège, Belgium, Hyloris has a patented portfolio of 19 reformulated and repurposed medicines and is involved in early phases of commercialisation for products like Sotalol IV and Maxigesic IV.

YTD Price Performance: -26.89%

Average Trading Volume: 552

Technical Sentiment Consensus Rating: Buy

Current Market Cap: €150.6M

See more insights into 52U stock on TipRanks’ Stock Analysis page.